## Practical Translation Assessment
### Druggability Considerations
This hypothesis is fundamentally a **biomarker strategy, not a drug target**. The biomarkers (Aβ42/Aβ40 ratio, p-tau181, p-tau217) are downstream readouts—they cannot be "modulated" directly. Druggability applies to the upstream pathology: amyloid plaques (lecaneumab, donanemab), tau tangles (Tau antibody programs from AC Immune, AbbVie). The composite index aims to *predict* who responds, not mechanistically intervene.
### Feasibility and Current State
**Emerging validation**: Plasma p-tau217 shows ~90-95% concordance with amyloid PET in recent studies (Jansen et al., 2023; Palmqvist et al., 2024). Multi-marker composites are already used—Eisai's lecanemab TRAILBLAZER trials integrated CSF and plasma biomarkers alongside PET endpoints. However, **no published head-to-head comparison demonstrates composite superiority over amyloid PET for treatment response prediction** in the same cohort.
**Regulatory acceptance remains uncertain**: The FDA has approved anti-amyloid drugs based on amyloid PET or CSF confirmation—not composite biomarker surrogates. plasma p-tau217 is not yet a validated surrogate endpoint (unlike HbA1c for diabetes).
### Competitive Landscape
- **C2N Diagnostics**: PrecivityAD (plasma Aβ42/40 + p-tau217) — already commercial
- **Fujirebio**: Plasma p-tau217 LLoW assay (FDA Breakthrough Device designation)
- **Alzheimer's Disease Neuroimaging Initiative (ADNI)**: Ongoing composite biomarker analyses
- **Roche/Genentech**: gantenerumab program driving biomarker endpoint exploration
### Cost/Timeline
- Plasma biomarker panels: $500-1,500 vs. amyloid PET at $3,000-5,000
- Composite index validation requires prospective trials: **5-7 years, $20-50M** per indication
- Adaptation to ongoing Phase III trials could accelerate validation to **2-3 years**
### Safety Concerns
If used to stratify patients for anti-amyloid therapy, false negatives could **delay treatment** in patients with prodromal AD, while false positives expose patients to unnecessary ARIA risk (amyloid-related imaging abnormalities), which occurs in 12-35% of lecanemab/donanemab recipients, with symptomatic ARIA in ~3%.
### Verdict
**Promising but premature.** The hypothesis has biological plausibility—p-tau217 outperforms amyloid burden for predicting downstream neurodegeneration. But claiming superiority over amyloid PET for treatment response prediction is a significant claim requiring prospective, adequately powered comparative studies. The translational value hinges on whether regulatory agencies accept the composite as a surrogate for drug approval, not just a research tool.